Characterising de novo donor-specific antibodies by IgG subclass
Research type
Research Study
Full title
Characterisation of de novo donor-specific antibodies by IgG subclasses in cardiothoracic recipients and possible associations with clinical outcome
IRAS ID
171872
Contact name
Yasmin Clinch
Contact email
Sponsor organisation
NHSBT
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
Up to 25% of transplant recipients develop immunoglobulin G (IgG) donor specific antibodies (DSA) post-transplant and up to 50% of these recipients will experience antibody-mediated rejection (ABMR) within the first year of transplant. Why every recipient with DSA does not experience rejection episodes or graft failure is not known. Despite substantial evidence that DSA and ABMR significantly reduce graft outcome and increase the risk of chronic rejection, it is unclear what antibody characteristics determine the highest risk of rejection or allograft loss. Therefore, there is a need to better differentiate clinically relevant DSA. On transplant waiting lists, all IgG subclasses have been found (IgG1-IgG4) in candidates and recipients in different proportions however studies have not yet yielded a consensus as to if a particular subclass is particularly associated with chronic rejection. My retrospective study aims to look at the types of IgG subclasses present in cardiothoracic recipients and see if there are any particular patterns of IgG subclass switching which may have a detrimental effect on their graft outcome.
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
15/SC/0672
Date of REC Opinion
27 Oct 2015
REC opinion
Favourable Opinion